Prosecution Insights
Last updated: July 17, 2026
Application No. 17/612,966

SYSTEMS AND METHODS FOR EVALUATING TUMOR FRACTION

Non-Final OA §DP
Filed
Nov 19, 2021
Priority
May 20, 2019 — provisional 62/850,474 +1 more
Examiner
VANNI, GEORGE STEVEN
Art Unit
1686
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Foundation Medicine Inc.
OA Round
2 (Non-Final)
67%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
398 granted / 595 resolved
+6.9% vs TC avg
Strong +24% interview lift
Without
With
+24.3%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
45 currently pending
Career history
631
Total Applications
across all art units

Statute-Specific Performance

§101
32.6%
-7.4% vs TC avg
§103
32.1%
-7.9% vs TC avg
§102
4.2%
-35.8% vs TC avg
§112
9.9%
-30.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 595 resolved cases

Office Action

§DP
DETAILED ACTION This application is being examined under AIA first-to-file provisions. Continued examination under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the previous allowance has been withdrawn pursuant to 37 CFR 1.114. MPEP 706.07(h) pertains. Status of claims Canceled: 18-33, 35, 39, 41-42, 44-56 and 58-59 Pending: 1-17, 34, 36-38, 40, 43 and 57 Withdrawn: none Examined: 1-17, 34, 36-38, 40, 43 and 57 Independent: 1, 17 and 57 Allowable: none Rejections applied Abbreviations 112/b Indefiniteness PHOSITA "a Person Having Ordinary Skill In The Art before the effective filing date of the claimed invention" 112/b "Means for" BRI Broadest Reasonable Interpretation 112/a Enablement, Written description CRM "Computer-Readable Media" and equivalent language 112 Other IDS Information Disclosure Statement 102, 103 JE Judicial Exception 101 JE(s) 112/a 35 USC 112(a) and similarly for 112/b, etc. 101 Other N:N page:line x Double Patenting MM/DD/YYYY date format Priority As detailed on the 7/12/2022 filing receipt, this application claims priority to as early as 5/20/2019. At this point in examination, all claims have been interpreted as being accorded this priority date. Nonstatutory double patenting The nonstatutory double patenting rejection is based on a judicially created doctrine to prevent the improper timewise extension of the "right to exclude" granted by a patent and to prevent multiple suits against an accused infringer by different assignees of the same invention (MPEP 804.II.B, 1st para.). A nonstatutory double patenting rejection is appropriate where the conflicting claims (instant v. reference) are not identical, but an examined-application claim (instant claim) is not patentably distinct from a reference claim because the instant claim is either anticipated by, or would have been obvious over, the reference claim (MPEP 804.II.B, 2nd para.). In cases of double patenting rejections versus reference claims of pending applications, as opposed to claims of an issued patent, the rejections are provisional because the reference claims have not been patented. Presently, no rejections are provisional. A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the application or patent of the reference claim either is shown to be commonly owned with the instant application or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must comply fully with 37 CFR 3.73(b). Applicant may wish to consider electronically filing a terminal disclaimer (MPEP 1490.V pertains, along with https://www.uspto.gov/patents-application-process/applying-online/eterminal-disclaimer). Electronic filing may lead to faster approval of the disclaimer. Also, if filing electronically, Applicant is encouraged to notify the examiner by telephone so that examination may resume more quickly. Double patenting rejections of instant claims 1-17, 34, 36-38, 40, 43 and 57 Instant claims 1-17, 34, 36-38, 40, 43 and 57 are rejected on the grounds of nonstatutory double patenting as unpatentable over one or more claims in reference application 19/171,081 in view of Wu (as cited on the 7/1/2025 IDS) and Annala (as cited on the 7/1/2025 IDS). The instant and reference applications have the same patent term filing dates (MPEP 804 I.B.1(b)(ii) pertains). The reference application recites claims which involve analyzing tumor fraction, beginning with allele fraction, including determination and use of a certainty metric, to determine tumor fraction. Although the reference claims are not identical to the instant claims, in a BRI they also are not patentably distinct from the instant claims: either (i) because the instant claims recite obviously equivalent or broader limitations in comparison to the reference claims or (ii) because the instant claims recite limitations which are obvious over the cited art. It is not clear that the instant claims recite limitations which are narrower than limitations in the reference claims. It would have been obvious in view of the cited art to modify reference claims to arrive at the rejected instant claims. Either the instant limitations are interpreted as reading on a reference limitation, or the instant limitations would have been obvious in view of the cited art. That is, to the extent that any instant claims are narrower than reference claims, then any such narrowing would have been obvious over the cited art. Citations to art In the above citations to documents in the art, rejections refer to the portions of each document cited as example portions as well as to the entirety of each document, unless otherwise noted in the situation of lengthy, multi-subject documents. Other passages not specifically cited within a document may apply as well. Conclusion No claim is allowed. A shortened statutory period for reply is set to expire THREE MONTHS from the mailing date of this communication. Inquiries Information regarding the filing, management and status of patent applications which are published (available to all users) or unpublished (available to registered users) may be obtained from the Patent Center: https://patentcenter.uspto.gov. Further information is available at https://www.uspto.gov/patents/apply/patent-center, and information about filing in DOCX format is available at https://www.uspto.gov/patents/docx. The Electronic Business Center (EBC) at 866-217-9197 (toll-free) is available for additional questions, and assistance from a Customer Service Representative is available at 800-786-9199 (IN USA OR CANADA) or 571-272-1000. The examiner for this Office action, G. Steven Vanni, may be contacted at: (571) 272-3855 Tu-F 8-7 (ET). If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Larry D. Riggs, II, may be reached at (571) 270-3062. /G. STEVEN VANNI/Primary patents examiner, Art Unit 1686
Read full office action

Prosecution Timeline

Nov 19, 2021
Application Filed
Sep 10, 2025
Non-Final Rejection mailed — §DP
Jan 08, 2026
Response Filed
May 19, 2026
Request for Continued Examination
May 20, 2026
Response after Non-Final Action
Jun 01, 2026
Non-Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12651642
EARLY FUSION OF NATURAL AND PROTEIN LANGUAGE MODELS FOR GENERATIVE AI-BASED PROTEIN AND DRUG DESIGN
1y 1m to grant Granted Jun 09, 2026
Patent 12642457
PREDICTING FOOD MACRONUTRIENTS FROM BLOOD BIOMARKERS
6y 0m to grant Granted Jun 02, 2026
Patent 12646587
IDENTIFYING SIGNATURE SNIPPETS FOR NUCLEIC ACID SEQUENCE TYPES
5y 8m to grant Granted Jun 02, 2026
Patent 12637717
Method for Predicting Prognosis of Gastric Cancer Patient and Kit Therefor
3y 9m to grant Granted May 26, 2026
Patent 12626779
VIRTUAL INFERENCE OF PROTEIN ACTIVITY BY REGULON ENRICHMENT ANALYSIS
5y 7m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
67%
Grant Probability
91%
With Interview (+24.3%)
4y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 595 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month